|
1
|
Menendez D, Inga A and Resnick MA: The
expanding universe of p53 targets. Nat Rev Cancer. 9:724–737. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sabapathy K and Lane DP: Therapeutic
targeting of p53: All mutants are equal, but some mutants are more
equal than others. Nat Rev Clin Oncol. 15:13–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lawrence MS, Stojanov P, Mermel CH,
Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander
ES and Getz G: Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 variations in human
cancers: New lessons from the IARC TP53 database and genomics data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kruiswijk F, Labuschagne CF and Vousden
KH: p53 in survival, death and metabolic health: A lifeguard with a
licence to kill. Nat Rev Mol Cell Biol. 16:393–405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Merkel O, Taylor N, Prutsch N, Staber PB,
Moriggl R, Turner SD and Kenner L: When the guardian sleeps:
Reactivation of the p53 pathway in cancer. Mutat Res. 773:1–13.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Freed-Pastor WA and Prives C: Mutant p53:
One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petitjean A, Achatz MI, Borresen-Dale AL,
Hainaut P and Olivier M: TP53 mutations in human cancers:
Functional selection and impact on cancer prognosis and outcomes.
Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fong KM, Kida Y, Zimmerman PV, Ikenaga M
and Smith PJ: Loss of heterozygosity frequently affects chromosome
17q in non-small cell lung cancer. Cancer Res. 55:4268–4272.
1995.PubMed/NCBI
|
|
13
|
Olivier M, Eeles R, Hollstein M, Khan MA,
Harris CC and Hainaut P: The IARC TP53 database: New online
mutation analysis and recommendations to users. Hum Mutat.
19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baugh EH, Ke H, Levine AJ, Bonneau RA and
Chan CS: Why are there hotspot mutations in the TP53 gene in human
cancers? Cell Death Differ. 25:154–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Poeta ML, Manola J, Goldwasser MA,
Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D,
Saunders J, et al: TP53 mutations and survival in squamous-cell
carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehmann BD and Pietenpol JA: Targeting
mutant p53 in human tumors. J Clin Oncol. 30:3648–3650. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Canale M, Petracci E, Delmonte A, Chiadini
E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M,
et al: Impact of TP53 mutations on outcome in EGFR-mutated patients
treated with first-line tyrosine kinase inhibitors. Clin Cancer
Res. 23:2195–2202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH,
Kim CH and Lee JC: p53 enhances gefitinib-induced growth inhibition
and apoptosis by regulation of Fas in non-small cell lung cancer.
Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Molina-Vila MA, Bertran-Alamillo J, Gascó
A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L,
Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al:
Nondisruptive p53 mutations are associated with shorter survival in
patients with advanced non-small cell lung cancer. Clin Cancer Res.
20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma X, Le Teuff G, Lacas B, Tsao MS,
Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L,
Filipits M, et al: Prognostic and predictive effect of TP53
mutations in patients with non-small cell lung cancer from adjuvant
cisplatin-based therapy randomized trials: A LACE-Bio pooled
analysis. J Thorac Oncol. 11:850–861. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Labbé C, Cabanero M, Korpanty GJ, Tomasini
P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, et
al: Prognostic and predictive effects of TP53 co-mutation in
patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung
Cancer. 111:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scoccianti C, Vesin A, Martel G, Olivier
M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK and
Hainaut P; European Early Lung Cancer Consortium, : Prognostic
value of TP53, KRAS and EGFR mutations in nonsmall cell lung
cancer: The EUELC cohort. Eur Respir J. 40:177–184. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SY, Jeon HS, Hwangbo Y, Jeong JY, Park
JY, Lee EJ, Jin G, Shin KM, Yoo SS, Lee J, et al: The influence of
TP53 mutations on the prognosis of patients with early stage
non-small cell lung cancer may depend on the intratumor
heterogeneity of the mutations. Mol Carcinog. 54:93–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma X, Rousseau V, Sun H, Lantuejoul S,
Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le
Chevalier T, et al: Significance of TP53 mutations as predictive
markers of adjuvant cisplatin-based chemotherapy in completely
resected non-small-cell lung cancer. Mol Oncol. 8:555–564. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lomax ME, Barnes DM, Hupp TR, Picksley SM
and Camplejohn RS: Characterization of p53 oligomerization domain
mutations isolated from Li-Fraumeni and Li-Fraumeni like family
members. Oncogene. 17:643–649. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Phang BH, Othman R, Bougeard G, Chia RH,
Frebourg T, Tang CL, Cheah PY and Sabapathy K: Amino-terminal p53
mutations lead to expression of apoptosis proficient p47 and
prognosticate better survival, but predispose to tumorigenesis.
Proc Natl Acad Sci USA. 112:E6349–E6358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pavletich NP, Chambers KA and Pabo CO: The
DNA-binding domain of p53 contains the four conserved regions and
the major mutation hot spots. Genes Dev. 7:2556–2564. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dittmer D, Pati S, Zambetti G, Chu S,
Teresky AK, Moore M, Finlay C and Levine AJ: Gain of function
mutations in p53. Nat Genet. 4:42–46. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao X, Zhang Z, Zheng X, Xie F, Duan F,
Jiang L, Chuai S, Han-Zhang H, Han B and Sun J: Capture-based
targeted ultradeep sequencing in paired tissue and plasma samples
demonstrates differential subclonal ctDNA-releasing capability in
advanced lung cancer. J Thorac Oncol. 12:663–672. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Van der Auwera GA, Carneiro MO, Hartl C,
Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen
D, Thibault J, et al: From FastQ data to high confidence variant
calls: The Genome analysis toolkit best practices pipeline. Curr
Protoc Bioinformatics. 43:11.10.1–33. 2013.
|
|
34
|
Koboldt DC, Zhang Q, Larson DE, Shen D,
McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK:
VarScan 2: Somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22:568–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
1000 Genomes Project Consortium, ; Auton
A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini
JL, McCarthy S, McVean GA and Abecasis GR: A global reference for
human genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cingolani P, Platts A, Wang le L, Coon M,
Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for
annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila
melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6:80–92.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Newman AM, Bratman SV, Stehr H, Lee LJ,
Liu CL, Diehn M and Alizadeh AA: FACTERA: A practical method for
the discovery of genomic rearrangements at breakpoint resolution.
Bioinformatics. 30:3390–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
RStudio Team, . RStudio: Integrated
Development for R. RStudio, Inc., Boston, MA, 2015. http://www.rstudio.com/
|
|
41
|
Awad MM and Shaw AT: ALK inhibitors in
non-small cell lung cancer: Crizotinib and beyond. Clin Adv Hematol
Oncol. 12:429–439. 2014.PubMed/NCBI
|
|
42
|
Karachaliou N, Sosa AE and Rosell R:
Unraveling the genomic complexity of small cell lung cancer. Transl
Lung Cancer Res. 5:363–366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Remon J, Steuer CE, Ramalingam SS and
Felip E: Osimertinib and other third-generation EGFR TKI in
EGFR-mutant NSCLC patients. Ann Oncol. 29 (Suppl 1):i20–i27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang S, Benavente S, Armstrong EA, Li C,
Wheeler DL and Harari PM: p53 modulates acquired resistance to EGFR
inhibitors and radiation. Cancer Res. 71:7071–7079. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
VanderLaan PA, Rangachari D, Mockus SM,
Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi
SS and Costa DB: Mutations in TP53, PIK3CA, PTEN and other genes in
EGFR mutated lung cancers: Correlation with clinical outcomes. Lung
Cancer. 106:17–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iwama E, Sakai K, Azuma K, Harada D,
Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, et
al: Exploration of resistance mechanisms for epidermal growth
factor receptor-tyrosine kinase inhibitors based on plasma analysis
by digital polymerase chain reaction and next-generation
sequencing. Cancer Sci. 109:3921–3933. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Blandino G and Di Agostino S: New
therapeutic strategies to treat human cancers expressing mutant p53
proteins. J Exp Clin Cancer Res. 37:302018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kosaka T, Yatabe Y, Onozato R, Kuwano H
and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53
gene mutations in a large cohort of Japanese patients with
surgically treated lung adenocarcinoma. J Thorac Oncol. 4:22–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trbusek M, Smardova J, Malcikova J,
Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Francova HS,
Doubek M, et al: Missense mutations located in structural p53
DNA-binding motifs are associated with extremely poor survival in
chronic lymphocytic leukemia. J Clin Oncol. 29:2703–2708. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Szymanowska A, Jassem E, Dziadziuszko R,
Skrzypski M, Kobierska-Gulida G, Holm K, Borg A, Rzyman W, Limon J
and Jassem J: Analysis of prognostic value of TP53 gene mutations
in non-small cell lung cancer. Pneumonol Alergol Pol. 73:264–269.
2005.(In Polish). PubMed/NCBI
|
|
51
|
Ahrendt SA, Hu Y, Buta M, McDermott MP,
Benoit N, Yang SC, Wu L and Sidransky D: p53 mutations and survival
in stage I non-small-cell lung cancer: Results of a prospective
study. J Natl Cancer Inst. 95:961–970. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang C, Taki T, Adachi M, Konishi T,
Higashiyama M and Miyake M: Mutations in exon 7 and 8 of p53 as
poor prognostic factors in patients with non-small cell lung
cancer. Oncogene. 16:2469–2477. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Skaug V, Ryberg D, Kure EH, Arab MO,
Stangeland L, Myking AO and Haugen A: p53 mutations in defined
structural and functional domains are related to poor clinical
outcome in non-small cell lung cancer patients. Clin Cancer Res.
6:1031–1037. 2000.PubMed/NCBI
|
|
54
|
Lim EH, Zhang SL, Li JL, Yap WS, Howe TC,
Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, et al: Using whole genome
amplification (WGA) of low-volume biopsies to assess the prognostic
role of EGFR, KRAS, p53, and CMET mutations in advanced-stage
non-small cell lung cancer (NSCLC). J Thorac Oncol. 4:12–21. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vikhanskaya F, Lee MK, Mazzoletti M,
Broggini M and Sabapathy K: Cancer-derived p53 mutants suppress
p53-target gene expression-potential mechanism for gain of function
of mutant p53. Nucleic Acids Res. 35:2093–2104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kim MP, Zhang Y and Lozano G: Mutant p53:
Multiple mechanisms define biologic activity in cancer. Front
Oncol. 5:2492015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S,
Xu J, Feng J and Liu B: TP53 mutation is associated with a poor
clinical outcome for non-small cell lung cancer: Evidence from a
meta-analysis. Mol Clin Oncol. 5:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Murakami I, Hiyama K, Ishioka S, Yamakido
M, Kasagi F and Yokosaki Y: p53 gene mutations are associated with
shortened survival in patients with advanced non-small cell lung
cancer: An analysis of medically managed patients. Clin Cancer Res.
6:526–530. 2000.PubMed/NCBI
|
